Lexicon Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Lexicon Pharmaceuticals, Inc. invites stockholders to its 2026 annual meeting to vote on director elections, an increase in authorized common stock, new equity incentive plans, executive compensation, and auditor ratification.
NASDAQ
Lexicon Pharmaceuticals has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.
NASDAQ
Lexicon Pharmaceuticals is asking stockholders to approve a reverse stock split and amendments to its equity incentive plans at its upcoming annual meeting.
NASDAQ
Lexicon Pharmaceuticals has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.
NASDAQ
Lexicon Pharmaceuticals is holding its annual stockholder meeting on May 10, 2024, to vote on key proposals including director elections, increasing authorized shares, executive compensation, and auditor ratification.